Description:
FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
Hereditary Cancers |
| Class |
Heritable Cancer Syndromes and other Cancers |
|
Cell Type
|
Fibroblast
|
|
Transformant
|
Untransformed
|
|
Race
|
White
|
|
Family Member
|
1
|
|
Relation to Proband
|
son
|
|
Confirmation
|
Clinical summary/Case history
|
|
ISCN
|
46,XY,t(1;10)(1pter>1q32::10p15> 10pter;10qter>10p15::1q32>1qter)[4]/46,XY[46]
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| Passage Frozen |
2 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Chromosome Analysis |
| |
| Gene |
APC |
| Chromosomal Location |
5q21-q22 |
| Allelic Variant 1 |
611731.0014; ADENOMATOUS POLYPOSIS COLI |
| Identified Mutation |
GLN541TER; In a Dutch family with APC, Fodde et al. [Genomics 13: 1162-1168 (1992)] identified a CAG-to-TAG change in codon 541 converting glutamine to a stop codon. Hamilton et al. [New Eng. J. Med. 332: 839-847 (1995)] found the same mutation in a family with Turcot syndrome with medulloblastoma (their family 7). |
| Remarks |
See GM03224 Lymphoid; normal sensitivity to MNNG produced loss of colony-forming ability; 46,XY; 8% of fibroblasts are 46,XY,t(1;10)(q32;p15); unbalanced; 7% are polyploid; donor subject has a C>T change at nucleotide 1621 in exon 12 of the APC gene (1621C>T) resulting in the conversion of a glutamine at codon 541 to a stop codon [Gln541Ter (Q541X)] |
| Nagasawa H, Little JB, Suppression of cytotoxic effect of mitomycin-C by superoxide dismutase in Fanconi's anemia and dyskeratosis congenita fibroblasts. Carcinogenesis4:795-9 1983 |
| PubMed ID: 6409437 |
| Passage Frozen |
2 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Substrate |
None specified |
| Subcultivation Method |
trypsin-EDTA |
| Supplement |
- |
|